AUG 07, 2018 8:15 AM PDT

Is There a Best Time of Day to Administer Chemo?

WRITTEN BY: Mauri Brueggeman

A recent publication in the Journal of Pharmacological Sciences outlines how the efficacy of L-asparaginase is dose schedule dependent in breast-tumor bearing mice.

Asparagine is an amino acid involved in metabolic control of cell functionality in primarily nerve and brain tissue.  It is a common, non-essential amino acid synthesized by the body from oxaloacetate, which is an intermediate of the citric acid cycle in aerobic glycolysis (ATP producing pathway).  L-asparaginase is an enzyme that enhances the conversion of asparagine which is used by new cells for growth and energy for proliferation.  Without asparagine, DNA and RNA synthesis cease which results in programmed cell death.  Young, undifferentiated lymph cells (lymphoblasts) in particular are dependent on asparagine for energy.   L-asparaginase has been used for nearly a decade in patients with acute lymphoblastic leukemia (ALL) with significant success as a multi-drug chemotherapy treatment.  Researchers have been looking at its use for solid tumors in vitro but have not translated results to in vivo studies for tumor bearing patients. 

A group of Japanese researchers sought to further the understanding of L-asparaginase as a chemotherapy agent for solid tumors through investigation of its mechanism and potential efficacy dependence on changing physiological levels of asparagine in plasma.  In animals, asparagine levels in plasma vary; they are higher in the light phase of a day and much lower in the dark phase of a day. 

They specifically looked at breast-tumor cells and the anti-tumor effects of L-asparaginase in mice while varying the administration schedule to track effect.  The group maintained the mice in standardized light/dark cycle conditions to mimic days and nights.  Tumor cell growth in these mice was significantly inhibited by L-asparaginase when administered during the light cycle hours; conversely, when L-asparaginase was administered in the dark phase, there was no significant anti-tumor activity.  The evidence very clearly suggests differences in anti-tumor therapeutic efficacy of L-asparaginase in these tumorigenic mice based on when doses were given. 

It is not clear if dose schedule is considered for many chemotherapeutic agents in a clinical setting, nor if there is other research showing the value of investigating such concepts.  It is noteworthy to consider if a cancer driving mechanism has any circadian rhythm or regular pattern with potential to affect therapy outcomes.

Sources: Journal of Pharmacological Sciences, NIH PubChem, Polish Archives of Internal Medicine,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
DEC 14, 2019
Cancer
DEC 14, 2019
Common antibiotic could improve radiation therapy
Have you ever taken the antibiotic vancomycin? As a commonly prescribed antibiotic for colitis and infections caused by Clostridium difficile, vancomycin i...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 05, 2020
Cancer
JAN 05, 2020
Good news for patients with testicular cancer!
Good news for patients with testicular cancer! A new clinical trial has shown that using just half of the quantity of chemotherapy traditionally administer...
JAN 14, 2020
Cancer
JAN 14, 2020
Could the flu vaccine shrink cancer tumors?
If you’ve been to the doctor recently, you’ve probably been asked if you want a flu shot this year. The flu vaccine is popular because it reduc...
FEB 16, 2020
Cancer
FEB 16, 2020
Digital biopsies: coming soon to clinics near you
Research published recently in the Proceedings of the National Academy of Sciences reports the development of a digitized biopsy, one that could be co...
Loading Comments...